Breast Cancer | Specialty

Neoadjuvant Therapy for HER2+ Breast Cancer

February 2nd 2016

MARIANNE and BOLERO-1 Trial Results in Breast Cancer

February 2nd 2016

First-Line Treatment of HER2-Positive MBC

February 2nd 2016

Managing Mouth Sores in Patients with Breast Cancer

February 2nd 2016

Review of Clinical Data on Palbociclib in Breast Cancer

February 2nd 2016

The Role of Fulvestrant in Metastatic HR+ Breast Cancer

February 2nd 2016

Appropriate Duration of Endocrine Therapy in Breast Cancer

February 2nd 2016

Managing Luminal A and Luminal B Breast Cancer

February 2nd 2016

Genomic Testing in Breast Cancer

February 2nd 2016

Treating Intermediate Risk Individuals with Breast Cancer

February 2nd 2016

Borgen Blasts USPSTF Breast Cancer Screening Guidelines

February 1st 2016

Patrick I. Borgen, MD, explains his strong opposition to the USPSTF guidelines and view that annual mammograms must remain a standard in clinical practice.

Breast Cancer Chemoprevention: Targeting the Estrogen Receptor

January 31st 2016

New strategies to increase the uptake of these proven breast cancer risk-reduction interventions in general clinical practice are needed.

Olaparib Studies Put Focus on BRCA-Positive Breast Cancers

January 30th 2016

The identification of the BRCA1 and BRCA2 tumor suppressor genes and the recognition that inherited loss of function (deleterious) mutations in one of these important genes places women at high risk for the development of breast, ovarian, and other cancers are major advances in women’s health research.

Dr. Aditya Bardia on RAD1901 in ER-Positive Metastatic Breast Cancer

January 29th 2016

Aditya Bardia, MD, MPH, assistant professor of Medicine, Harvard Medical School, attending physician, Medical Oncology, Massachusetts General Hospital, discusses RAD1901, a selective estrogen receptor degrader (SERD) for potential use in ER-positive metastatic breast cancer.

HER2 Subtype Offers Clues for Individualizing Breast Cancer Care

January 29th 2016

One-third of patients previously identified as having HER2-positive breast cancer were found to also have a luminal subtype that was resistant to chemotherapy and trastuzumab but still sensitive to the triplet neoadjuvant regimen of pertuzumab, trastuzumab, and chemotherapy.

Dr. Peter Beitsch on Pertuzumab in Luminal Subtype Breast Cancer

January 18th 2016

Peter Beitsch, MD, President at The American Society of Breast Surgeons, Dallas Surgical Group, discusses the impact of pertuzumab on patients with luminal subtype breast cancer.

Study Reveals New Potential Breast Cancer Drug Combinations

January 18th 2016

The largest analysis of breast cancer cell function to date suggests dozens of new uses for existing drugs, new targets for drug discovery, and new drug combinations.

Dr. Danciu on Prescreening and Identifying Breast Cancer Survivors

January 18th 2016

Oana C. Danciu, MD, assistant professor of Medicine, Division of Hematology/Oncology, University of Illinois Hospital and Health Sciences System, discusses a study examining a team-based approach to prescreen and identify breast cancer survivors using a survivorship care plan.

A Second Chance

January 17th 2016

Tailoring your approach to how you interact with a patient can be beneficial.

Expert Explains USPSTF Breast Cancer Screening Guidelines

January 15th 2016

Anees B. Chagpar, MD, shares her thoughts on the final US Preventive Services Task Force guidelines and how they change the focus of breast cancer screening.